News

FDA Expands Moderna's RSV Vaccine Use To At-Risk Adults Aged 18–59 Amid CDC Panel Shake-Up
The U.S. Food and Drug Administration expanded approval of Moderna Inc.'s (NASDAQ: MRNA) respiratory syncytial virus vaccine.
FDA expands Moderna's RSV vaccine approval to at-risk adults
The U.S. Food and Drug Administration has approved Moderna’s (NASDAQ:MRNA) RSV vaccine, mRESVIA (mRNA-1345), for preventing ...